Wednesday, February 20, 2013 (Last Updated: 02/21/2013)
The American Society of Clinical Oncology's annual Genitourinary Cancers Symposium was held from Feb. 14 to 16 in Orlando, Fla., and attracted more than 2,000 participants from around the world. The conference highlighted recent advances in the diagnosis, prevention, and management of genitourinary cancers, including prostate, kidney, bladder, and testicular, as well as less common cancers such as those of the penis, ureters, and other urinary organs.
In one study, Asim Amin, M.D., of the Carolinas Medical Center in Charlotte, N.C., and colleagues found that immunotherapy with AGS-003 may safely be combined with sunitinib without any additional toxicity. In addition, the investigators also found that the addition of immunotherapy to sunitinib may confer durability to responses compared to those observed with sunitinib alone.
"Using the combination of a novel patient specific immunotherapy, AGS-003 (autologous dendritic cells loaded with autologous tumor mRNA) with standard of care vascular endothelial growth factor tyrosine kinase inhibitor sunitinib in poor and intermediate risk (by Heng criteria) patients with advanced renal cell carcinoma, the overall response was 43 percent," Amin said. "The median progression-free survival (PFS) was 11.2 months and overall survival (OS) was 30.2 months for the entire group. Stratifying by risk, the median OS for poor-risk patients was 9.1 months and the OS for the intermediate-risk patients was not reached but estimated at 39.5 months. Statistically significant correlation was noted between the absolute increase in memory T cells and response. There were no grade 3/4 toxicities attributed to the immunotherapy component; expected toxicities from sunitinib were noted."
Several authors disclosed financial ties to Argos Therapeutics and other pharmaceutical companies.
In another study, William C. Huang, M.D., of the New York University Langone Medical Center and Cancer Institute in New York City, and colleagues evaluated a population-based data set of older patients with small kidney tumors (less than 4 cm) to assess outcomes in those who underwent surgical treatment versus surveillance.
"We observed that treatment with surveillance did not adversely impact cancer-specific survival compared to surgical treatment. Cancer-specific survival was essentially identical regardless of treatment choice. Interestingly, in our study, patients who underwent surveillance were less likely over time to suffer a cardiovascular event and less likely to die," said Huang. "Based on our study findings, surveillance is a reasonable option for the management of small renal masses in patients with a limited life expectancy such as older patients and those with significant comorbid illness. I would warn that the findings of our study do not apply to younger patients or healthy patients who have a prolonged life expectancy, because we cannot accurately predict which patients with small tumors will eventually go on to die of kidney cancer if left untreated."
Matthew R. Cooperberg, M.D., M.P.H., of the University of California in San Francisco, and colleagues found that the biopsy-based genomic prostate score (GPS) was a good predictor of high-grade or extracapsular prostate cancer.
"GPS is a validated, biopsy-based predictor of adverse prostate cancer pathology," Cooperberg and colleagues note. "Incorporating GPS with clinical data provides substantially improved risk discrimination and enables more accurate identification of a larger population of patients who can choose active surveillance more confidently as an initial management strategy."
Several authors disclosed financial ties to various pharmaceutical and diagnostic companies.
ASCO: Anticoagulant Use Predicts Metastatic Prostate CA Survival
TUESDAY, Feb. 19 (HealthDay News) -- Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
ASCO: Finasteride Reduces Risk of Prostate Cancer Diagnosis
TUESDAY, Feb. 19 (HealthDay News) -- Use of finasteride reduces the risk of a prostate cancer (PCa) diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to a study presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
ASCO: Many Still Diagnosed With Higher-Risk Prostate Cancer
WEDNESDAY, Feb. 13 (HealthDay News) -- Men over the age of 75 years and black men have the highest likelihood of diagnosis with intermediate- or high-risk prostate cancer, according to a study presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
ASCO: Surveillance Viable for Small Renal Masses in Elderly
WEDNESDAY, Feb. 13 (HealthDay News) -- For elderly patients with small renal masses, surveillance does not adversely affect kidney cancer-specific survival, and is associated with lower all-cause mortality and risk of cardiovascular events, according to a study presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
ASCO: OK to Shorten Androgen Blockade in High-Risk Prostate CA
WEDNESDAY, Feb. 13 (HealthDay News) -- For men with high-risk prostate cancer undergoing pelvic radiotherapy and hormone therapy, outcomes are similar with long- (36 months) or short- (18 months) duration androgen blockade therapy, according to a study presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.
Hematology & Oncology